NSE: RPGLIFE · BSE: 532983
RPG LIFE SCIENCES LTD
Sells branded pharmaceutical formulations in India and abroad, and through mid-2026 also manufactured active pharmaceutical ingredients (APIs). Domestic Formulations is the largest segment — it markets chronic-therapy drugs under brands such as Naprosyn, launched a new Naprosyn ES (Naproxen + Esomeprazole) combination in July 2026 through a partnership with Archerchem, and is scaling an immunosuppressant portfolio. International Formulations exports formulations to overseas markets. The API business, which contributed Rs 95.06 crore (13.54% of FY26 consolidated revenue), is being transferred on a slump sale basis to a newly formed wholly owned subsidiary, RPG Active Pharma, in which PE investors are committing up to Rs 700 crore; the same subsidiary is separately acquiring 100% of Actis Generics for Rs 80 crore in cash. Raw materials (19.2% of revenue) and employees (20.0% of revenue) are the largest operating costs, with capex at 9.2% and depreciation at 3.0% of revenue. FY26 consolidated revenue totalled Rs 707.52 crore, with Domestic Formulations at Rs 483.5 crore growing 13.8% year-on-year while International Formulations declined 6.7%. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Domestic Formulations, International Formulations, API (Active Pharmaceutical Ingredients) (14%). Branded formulations-focused Indian pharma company, mid-scale, with the API business being carved out into a separately funded subsidiary
Exhibit 1: Financial summary, FY26–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 708 |
| EBITDA (ex other income) | 151 |
| margin % | 21.3 |
| Owners' profit | 115 |
| EPS, as reported (₹) | 18.08 |
| ROE % · ROCE % | 19.0 · 24.5 |
| Debt / equity (x) | 0.03 |
| Cash from operations | 57 |
| Capex | (65) |
Exhibit 2: Quarterly performance, last 3 quarters
| ₹ crore | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 180 | 177 | 196 |
| Profit before tax | 29 | 40 | 41 |
| Net profit | 22 | 30 | 31 |
| EPS (₹) | 13.38 | 18.08 | 18.60 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,21,677 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,53,976 | 87.0 | 15.15 | 65.5 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,54,957 | 73.1 | 8.81 | 38.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| LAURUS LABS LIMITED | 1,17,877 | 107.7 | 21.70 | 65.6 | 16.4 | 17.2 | 7.2 | 32.0 |
| ZYDUS LIFESCIENCES LTD | 1,17,315 | 26.2 | 3.97 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| DR. REDDY S LABORATORIES | 1,11,506 | 34.5 | 2.92 | 14.9 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,10,320 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,02,829 | 50.3 | 6.21 | 28.3 | 11.7 | 10.8 | — | 27.3 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 57.0 | 30.8 | 123 of 158 | 22% |
| P/B | 7.8 | 3.1 | 141 of 163 | 14% |
| ROCE | 24.4 | 10.8 | 17 of 183 | 91% |
| ROE | 19.0 | 9.8 | 21 of 166 | 88% |
| Debt / Equity | 0.0 | 0.2 | 57 of 166 | 66% |
| EBITDA margin | 24.5 | 17.5 | 56 of 165 | 67% |
| Market cap | 4719 | 806 | 58 of 181 | 68% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 23 Oct 2026 · RPG Life Sciences schedules Q2 FY27 earnings call | board shareholder meetings | low | — | — |
| 22 Oct 2026 · Board meeting to approve September 2026 results | results | low | — | — |
| 8 Oct 2026 · Routine dematerialisation compliance certificate for Q2 FY27 | compliance | minimal | — | — |
| 30 Sept 2026 · Newspaper ad on special window for transfer and demat of old physical shares | compliance | minimal | — | — |
| 28 Sept 2026 · RPG Life Sciences SAST disclosure by Clarus Capital I filed with BSE | ownership changes | medium | — | — |
| 26 Sept 2026 · RPG Life Sciences: Subsidiary merger scheme approved by board | strategic transactions | high | — | — |
| 25 Sept 2026 · Trading Window closed ahead of Q2 and H1 FY27 results | compliance | minimal | — | — |
| 24 Sept 2026 · RPG Life Sciences completes Actis Generics acquisition | strategic transactions | high | — | — |
| 23 Sept 2026 · Clarification on unusual trading volume - no pending material info | compliance | low | — | — |
| 23 Sept 2026 · NSE seeks clarification from RPG Life Sciences on unusual volume | general | medium | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.